Relief Therapeutics Holding AG (RLFTF)

[Gls3ms]

Good morning Team,

Myself along with others sent out a first draft copy of RLFTF’s study in 21 patients. The one below is the actual paper that went out this morning. There are several important updates and clarifications. The news is “Striking” as noted in the paper.


https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228

If you are interested in this stock you need to read this paper. If you are ready to invest in other stocks that will rise when we get a Covid treatment that will get the economy back to full throttle you may be looking at it right here. The paper makes note that this
Drug has shown in the past and may in the future be used for all sorts of other pulmonary issues. I am so very pleased with this outcome. Here are some excerpts.


“Comment: The short term outcomes in these 21 patients represent a dramatic response in patients who are excluded from all other trials of COVID therapeutics. Improvement in radiographic appearance, oxygenation requirement, and inflammatory markers is consistent with in vitro evidence of direct anti-viral effect.”


“Clinical Results
Median patient follow-up time is 21 days. So far, 19 of 21 patients have survived. One death was due to COVID-related multisystem organ failure and the other (on ECMO) to an underlying and unrelated encephalopathy.
Twenty of 21 patients demonstrated improvement in blood oxygenation (Fig 1). The improvement in patients on ECOM was similar to that seen in patients treated with conventional mechanical ventilation. Available data from blood gases showed stark increases in PaO2:FiO2 ratio after the 2nd dose (Median increase = 92.5, IQR = 74) and at 24 hours after the 3rd dose (Median increase over baseline 84.5, IQR = 110). No patient showed deterioration of oxygenation below baseline during subsequent measurements.
Radiographic evidence (Fig 2) on all patients is included in the online supplementary material. Full or partial resolution of the “ground glass” parenchymal changes associated with COVID-19”


“The significant clinical improvement seen in these 21 patients treated with intravenous RLF-100TM (aviptadil), is consistent with the finding that VIP both blocks viral replication in pulmonary ATII and creates a “bystander effect” whereby nearby monocytes secrete soluble antiviral agents to further protect ATII cells, blocks cytokine storm, and improves oxygenation in a lung that is under attack by the SARS-CoV-2 virus. The rapidity and magnitude of clinical effect has not been reported to our knowledge in association with any other COVID-19 therapeutic agent, suggesting a highly specific role of VIP in combating the lethal effects of SARS-CoV-2 infection.”


“The clinical course of the patients in this study, with some having demonstrated rapid clinical recovery and discharge to home while others continue to improve more slowly, is striking for the consistency of improvement on radiographic changes, blood levels of inflammatory markers, and improvement in blood oxygenation. The radiographic improvement seen in these patients, is highly atypical for COVID-19 and suggests that aviptadil may be effective in treating COVID-19 and has substantial potential to demonstrate efficacy in adequately-controlled trials.”

“Aviptadil may have further value as a nasopharyngeal drug to prevent SARS-CoV-2 from successfully infecting nasopharyngeal cells and starting the pathogenic process of COVID-19. Moreover, aviptadil may have promise in treating a broad array of pulmonary inflammatory conditions.”


It may take a little time to get this main stream but we should see and hear much more in the following weeks. The biggest take away is that this study was on the worst of the worst patients. Imagine the trial results in folks that are generally healthy and not in need of ventilation and ECMO. I really think we have found the best therapeutic for this pandemic.